Related Experiment Video

Updated: Apr 29, 2026

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel
06:44

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel

Published on: September 8, 2017

14.0K

Synthesis and anticancer activity of novel quinoline-docetaxel analogues

Ming Chen1, Hui Chen1, Jiangwei Ma1

  • 1Department of Medicinal Chemistry, School of Pharmacy, Fourth Military Medical University, 169 Changle Road, Xian 710032, People's Republic of China.

Bioorganic & Medicinal Chemistry Letters
|May 20, 2014
PubMed

Insights

Novel quinoline-docetaxel analogues show potent anticancer activity, outperforming docetaxel against various cancer cell lines, including drug-resistant strains. Compound 6c demonstrated significant efficacy, highlighting the potential of quinoline scaffolds in cancer therapy.

Area of Science:

  • Medicinal Chemistry
  • Pharmacology
  • Oncology

Background:

  • Docetaxel is a widely used chemotherapy drug, but its efficacy can be limited by drug resistance.
  • Quinoline scaffolds are known for their diverse biological activities, including anticancer properties.

Purpose of the Study:

  • To design and synthesize novel quinoline-docetaxel analogues.
  • To evaluate the anticancer activities of these analogues against various human cancer cell lines, including multidrug-resistant strains.

Main Methods:

  • Synthesis of quinoline-docetaxel analogues by attaching bioactive quinoline scaffolds to docetaxel.
  • In vitro cytotoxicity assays using Hela, A549, A2780, MCF-7, A2780-MDR, and MCF-7-MDR cancer cell lines.

Main Results:

  • Novel analogues (6a-6g, 13a-13g) were successfully synthesized.
  • Most analogues exhibited comparable or superior cytotoxicity to docetaxel.
  • Compound 6c showed remarkable potency against MCF-7-MDR cells (IC50 = 8.8 nM) compared to docetaxel (IC50 = 180 nM).

Conclusions:

  • Introduction of a quinolyl group enhances docetaxel's cytotoxicity.
  • Quinoline-docetaxel analogues demonstrate potential in overcoming drug resistance.
  • These findings suggest a promising new direction for developing more effective anticancer agents.
Keywords:
AnticancerCytotoxicityDocetaxelDrug-resistanceQuinoline

More Related Videos

Functionalized Spirocyclic Heterocycle Synthesis and Cytotoxicity Assay05:17

Functionalized Spirocyclic Heterocycle Synthesis and Cytotoxicity Assay

Published on: February 9, 2021

1.7K
An In Vitro Enzymatic Assay to Measure Transcription Inhibition by GalliumIII and H3 5,10,15-trispentafluorophenylcorroles09:00

An In Vitro Enzymatic Assay to Measure Transcription Inhibition by GalliumIII and H3 5,10,15-trispentafluorophenylcorroles

Published on: March 18, 2015

11.1K

Related Concept Videos

Inhibitors of Bacterial DNA Synthesis01:28

Inhibitors of Bacterial DNA Synthesis

Bacterial pathogens depend on precise and efficient DNA replication to sustain infection. Two type II topoisomerases—DNA gyrase and topoisomerase IV—are critical to this process, as they resolve DNA supercoiling and unlink chromosomes during replication. Fluoroquinolones, synthetic derivatives of quinolones, exploit this mechanism by stabilizing the transient DNA–enzyme cleavage complex, preventing strand religation, and causing lethal double-strand breaks. These...
128
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.2K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.0K
Drugs that Destabilize Microtubules01:10

Drugs that Destabilize Microtubules

Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
3.2K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
8.3K